Entrada Therapeutics Appoints Gina Chapman to its Board of Directors - Entrada Therapeutics (NASDAQ:TRDA) benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the United Kingdom in September 2023 – – $377 million in cash, cash equivalents and marketable securities as of June 30, 2023 – – Cash
Entrada Therapeutics (NASDAQ:TRDA) Shares Up 7 5% theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $14.48, but opened at $13.19. Entrada Therapeutics shares last traded at $15.08, with a volume of 44,361 shares traded. Analysts Set New Price Targets Several brokerages recently issued reports on TRDA. […]
BOSTON, Mass., June 06, 2023 Entrada Therapeutics, Inc. , a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle. | June 6, 2023